Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2010 - 2025)

Rigel Pharmaceuticals' Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.0 million for Q1 2025.

• In Q1 2025, Other Non-Current Liabilities fell 87.49% year-over-year to $5.0 million; the TTM figure through Mar 2025 stood at $5.0 million (down 87.49% YoY), while the FY2024 annual figure was $40.0 million, changed 0.09% from the prior year.
• Other Non-Current Liabilities was $5.0 million for Q1 2025 at Rigel Pharmaceuticals, down from $40.0 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $57.5 million in Q1 2021 to a low of $5.0 million in Q1 2025.
• Historically, Other Non-Current Liabilities has averaged $43.0 million across 5 years, with a median of $42.1 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities jumped 1050.66% in 2021, then sank 87.49% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $52.7 million in 2021, then declined by 19.84% to $42.3 million in 2022, then declined by 5.49% to $39.9 million in 2023, then grew by 0.09% to $40.0 million in 2024, then plunged by 87.49% to $5.0 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $5.0 million (Q1 2025), $40.0 million (Q4 2024), and $40.0 million (Q3 2024), per Business Quant data.